Navigation Links
Sequenom to Host Analyst Day on Monday, November 14, 2011
Date:11/14/2011

SAN DIEGO, Nov. 14, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it will host an Investor and Analyst Day at NASDAQ Tower in New York on Monday, November 14, 2011 from 2:00 to 5:00 pm ET. Key members of the company's management team will offer an in-depth discussion of the business, specifically focusing on the recent commercial launch of the MaterniT21 laboratory developed test (LDT).

Space for the event is limited and, therefore, by invitation only.  For those who cannot attend, the presentation will be web cast live through the "Investor Relations" section of the Sequenom website at www.sequenom.com.  An audio replay will be available for 30 days following the initial presentation web cast. 

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
3. Sequenom Center for Molecular Medicine Announces Launch of MaterniT21™ Noninvasive Prenatal Test for Down Syndrome
4. Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System
5. Sequenom, Inc. Announces Date of Second Quarter 2011 Financial Results and Conference Call
6. Sequenom Enters Into New $30.0 Million Credit Facility
7. Sequenom Announces Participation at Jefferies 2011 Global Healthcare Conference
8. Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study
9. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
10. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
11. Sequenom Announces Formation of Ophthalmology Clinical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):